Type 2 diabetes patients assessment of the COMODITY12 mHealth system.
DOI:
https://doi.org/10.4108/icst.pervasivehealth.2015.259283Keywords:
mhealth, comodity12, diabetesAbstract
Background: Patient acceptance is one of the major barriers toward widespread use of mHealth. The aim of this study was to assess patients’ experience with their use of COMMODITY12 telehealth system. Methods: DM2 patients assessed COMMODITY12 system after its 6 weeks’ long use within clinical trial. Patients opinions were collected with 7-item questionnaire, assessing different aspects of system use, as well as EuroQol-5D-5L generic questionnaire, assessing health-related quality of life. Results: Thirty patients (female, 13, male, 17, mean age +/- SD 59.9 +/- 5.3) completed study. All dimensions of experience with system use were assessed well, with maximum values for clearness of instructions, and ease of use (4.80, and 4.63, respectively). Health related quality of life, as assessed with general utility measure, improved significantly (P<0.05). Conclusions: Study proved that the COMODITY12 system is accepted well by type 2 diabetes patients taking part in clinical trial. Nevertheless, before future commercialisation of the system, several minor problems identified during the study need to be addressed.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 EAI Endorsed Transactions on Pervasive Health and Technology
This work is licensed under a Creative Commons Attribution 3.0 Unported License.
This is an open access article distributed under the terms of the CC BY-NC-SA 4.0, which permits copying, redistributing, remixing, transformation, and building upon the material in any medium so long as the original work is properly cited.